neuropharmacology

Latest

neuropharmacology

Featured Neuroscience Open Neuroscience Articles Psychology

·June 1, 2020

How ketamine combats depression

Ketamine increases the number of serotonin 1B receptors. Ketamine binds to serotonin 1B receptors, reducing the release of serotonin and increasing the release of dopamine. Read More

Brain Cancer Featured Neurology Neuroscience Psychology

·May 1, 2020

Schizophrenia drug combined with radiation shows promise in treating deadly brain tumors

Trifluoperazine, a dopamine receptor antagonist commonly prescribed for schizophrenia, used in combination with radiation therapy delays the growth of glioblastoma brain tumors and prolongs survival for brain cancer. Read More

Featured Neurology pain

·April 30, 2020

A potential treatment for chronic pain

A newly developed peptide called Tat-P4-(C5)2 is targets and only affects nerve changes that pose a problem resulting in chronic pain. Previous studies have also shown the peptide can also reduce addiction. Read More

This shows the shadow of a man in a tunnel

Featured Neuroscience Open Neuroscience Articles Psychology

·April 29, 2020

Drug reduces risk of pedophiles re-offending

Degarelix, a drug that reduces testosterone levels, shows potential in the treatment of pedophilic disorder. Men with a history of child sexual abuse who took the drug had reduced overall sexual desire and decreased attraction toward children, with noticeable effects within two weeks. Read More

Brain Cancer Featured Neurology Neuroscience

·April 27, 2020

CBD shows promise for fighting aggressive brain cancer

Cannabidiol (CBD) appears to slow the growth of glioblastoma brain cancer cells in both animal and human cell lines. CBD's anti-cancer actions target mitochondria, causing them to dysfunction and release harmful reactive oxygen species. Cancer cells treated with CBD exhibited significant decreases in mitochondrial activity. Read More

Featured Genetics Neurology Neuroscience

·April 6, 2020

Alzheimer’s trial screening data links high amyloid levels with early stage disease

Findings support the hypothesis that higher levels of amyloid in the brain is an indicator of the early stages of Alzheimer's disease. Read More

Featured Neurology Neuroscience Open Neuroscience Articles

·March 31, 2020

Amyloid formation drives brain tissue loss

Animal study reveals the formation of amyloid plaques drives brain tissue loss and neurodegeneration in Alzheimer's disease. However, lithium, a drug commonly used to treat bipolar disorder, reduces the life-shortening effects of the loss. Read More

Featured Neurology Neuroscience

·March 28, 2020

FDA approves ozanimod for treatment of multiple sclerosis

The FDA has approved a new drug named Ozanimod for the treatment of multiple sclerosis. Ozanimod binds to receptors in lymphocytes' surfaces, preventing them from reaching the brain. As the number of active lymphocytes decreases, the attack on the immune system diminishes. Read More

This shows a man looking out of a window

Featured Neuroscience Open Neuroscience Articles Psychology

·February 20, 2020

Extended antidepressant use creates physical dependence

Long-term use of antidepressants can create physical dependence and severe withdrawal symptoms for patients looking to stop their treatment. Patients who quit their medication often experience Antidepressant Discontinuation Syndrome, which results in flu-like symptoms, insomnia, nausea, and other symptoms associated with withdrawal. Read More

Featured Neurology Neuroscience Open Neuroscience Articles

·February 16, 2020

Cough syrup drug being trialed as Parkinson’s treatment

Ambroxol, a medication approved to treat coughs, may slow the progression of Parkinson's disease. The medication is able to effectively cross the blood-brain barrier and increases levels of GCase in patients' brains. Ambroxol also appears to reduce Parkinson's-related alpha-synuclein levels. Read More

This shows a brain and a swirly background

Brain Cancer Featured Neuroscience Psychology

·February 2, 2020

Single dose of psilocybin reduces depression and anxiety for a year in cancer patients

A single dose of the psychedelic psilocybin reduces depression, anxiety, and feelings of hopelessness in cancer patients for 12 months after the drug is administered. Read More

This shows a psychedelic face and flowers

Featured Neuroscience Psychology

·January 28, 2020

Could psychedelics help treat mental health and resolve the climate crisis?

Numerous recent studies claim psychedelics, such as psilocybin, can help treat a range of mental health problems from depression to PTSD. Researchers investigate how psychedelics can help us become more "nature-connected" and increase a sense of environmental responsibility. Read More

1 2 3 … 44